Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
08 Feb 2024
08 Feb 2024
Historique:
received:
19
12
2022
accepted:
16
01
2024
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
8
2
2024
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC
Identifiants
pubmed: 38332002
doi: 10.1038/s41467-024-45241-y
pii: 10.1038/s41467-024-45241-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1173Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC 2155 RESIST, Project 390874280
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC 2155 "RESIST" - Project ID 390874280
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC 2155 "RESIST" - Project ID 390874280
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC 2155 "RESIST" - Project ID 390874280
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC 2155 "RESIST" - Project ID 390874280
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : EXC2155 RESIST_390874280
Organisme : Niedersächsisches Ministerium für Wissenschaft und Kultur (Ministry for Science and Culture of Lower Saxony)
ID : INDIRA 11-76251-99-6/19 (ZN3437)
Organisme : Volkswagen Foundation (VolkswagenStiftung)
ID : OPTIS, Project ID 9B811
Organisme : Volkswagen Foundation (VolkswagenStiftung)
ID : OPTIS, Project ID 9B811
Organisme : Volkswagen Foundation (VolkswagenStiftung)
ID : OPTIS, Project ID 9B811
Organisme : Volkswagen Foundation (VolkswagenStiftung)
ID : OPTIS, ID9B811
Organisme : Deutsches Zentrum für Infektionsforschung (German Center for Infection Research)
ID : DZIF, TTU 09.719
Organisme : Niedersächsische Ministerium für Wissenschaft und Kultur (Lower Saxony Ministry of Science and Culture)
ID : INDIRA 11-76251-99-6/19 (ZN3437)
Informations de copyright
© 2024. The Author(s).
Références
Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 388, 3027–3035 (2016).
pubmed: 27839855
pmcid: 5161777
doi: 10.1016/S0140-6736(16)31593-8
Mazur, N. I. et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir. Med 3, 888–900 (2015).
pubmed: 26411809
doi: 10.1016/S2213-2600(15)00255-6
Lange, M. et al. Non-Appearance of the RSV Season 2020/21 During the COVID-19 Pandemic-Prospective, Multicenter Data on the Incidence of Respiratory Syncytial Virus (RSV) Infection. Dtsch Arztebl Int. 118, 561–562 (2021).
pubmed: 34725031
pmcid: 8579425
Haapanen, M., Renko, M., Artama, M. & Kuitunen, I. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children—A nationwide register study in Finland. EClinicalMedicine 34, 100807 (2021).
pubmed: 33817612
pmcid: 8007090
doi: 10.1016/j.eclinm.2021.100807
Bardsley, M. et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis. 23, 56–66 (2023).
pubmed: 36063828
doi: 10.1016/S1473-3099(22)00525-4
van Summeren, J. et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Eur. Surveill. 26, 2100639 (2021).
Casalegno, J. S. et al. Characteristics of the delayed respiratory syncytial virus epidemic, 2020/2021, Rhone Loire, France. Eur. Surveill. 26, 2100630 (2021).
doi: 10.2807/1560-7917.ES.2021.26.29.2100630
den Hartog G, et al. Decline of RSV-specific antibodies during the COVID-19 pandemic. Lancet Infect Dis. 23, 23–25 (2023).
pubmed: 36463892
doi: 10.1016/S1473-3099(22)00763-0
Pinquier, D. et al. Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities. Infect. Dis. Ther. 12, 317–332 (2023).
pubmed: 36520324
doi: 10.1007/s40121-022-00737-2
Adams, O. et al. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin. Infect. Dis. 51, 185–188 (2010).
pubmed: 20528472
doi: 10.1086/653534
Ruckwardt, T. J. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines 8, 138 (2023).
pubmed: 37749081
pmcid: 10519952
doi: 10.1038/s41541-023-00734-7
Cockerill, G. S., Good, J. A. D. & Mathews, N. State of the art in respiratory syncytial virus drug discovery and development. J. Med. Chem. 62, 3206–3227 (2019).
pubmed: 30411898
doi: 10.1021/acs.jmedchem.8b01361
Alpana Waghmare JAE. 21—Respiratory viruses. Pediatric Transplant and Oncology Infectious Diseases. Ch. 21, 148-154.e143, (2021).
Domachowske, J. B., Anderson, E. J. & Goldstein, M. The future of respiratory syncytial virus disease prevention and treatment. Infect. Dis. Ther. 10, 47–60 (2021).
pubmed: 33656652
pmcid: 7926075
doi: 10.1007/s40121-020-00383-6
Risso-Ballester, J. et al. A condensate-hardening drug blocks RSV replication in vivo. Nature 595, 596–599 (2021).
pubmed: 34234347
doi: 10.1038/s41586-021-03703-z
Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl. Acad. Sci. USA 115, 10750–10755 (2018).
pubmed: 30282735
pmcid: 6196526
doi: 10.1073/pnas.1810137115
Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113–119 (2020).
pubmed: 32707573
pmcid: 7603405
doi: 10.1038/s41586-020-2577-1
DeVincenzo, J. P. et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N. Engl. J. Med. 371, 711–722 (2014).
pubmed: 25140957
doi: 10.1056/NEJMoa1401184
Chapman, J. et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 51, 3346–3353 (2007).
pubmed: 17576833
pmcid: 2043207
doi: 10.1128/AAC.00211-07
Bagchi, S., Rathee, P., Jayaprakash, V. & Banerjee, S. Farnesyl transferase inhibitors as potential anticancer agents. Mini Rev. Med. Chem. 18, 1611–1623 (2018).
pubmed: 30068272
doi: 10.2174/1389557518666180801110342
Dhillon, S. Lonafarnib: First Approval. Drugs 81, 283–289 (2021).
pubmed: 33590450
pmcid: 7985116
doi: 10.1007/s40265-020-01464-z
Pfefferle, S. et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011).
pubmed: 22046132
pmcid: 3203193
doi: 10.1371/journal.ppat.1002331
Haid, S., Grethe, C., Bankwitz, D., Grunwald, T. & Pietschmann, T. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system. J. Virol. 90, 3065–3073 (2015).
pubmed: 26719246
doi: 10.1128/JVI.03074-15
Cianci, C. et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 48, 413–422 (2004).
pubmed: 14742189
pmcid: 321540
doi: 10.1128/AAC.48.2.413-422.2004
Yan, D. et al. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc. Natl Acad. Sci. USA 111, E3441–E3449 (2014).
pubmed: 25092342
pmcid: 4143008
doi: 10.1073/pnas.1405198111
Zhu, Q. et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 203, 674–682 (2011).
pubmed: 21208913
pmcid: 3072724
doi: 10.1093/infdis/jiq100
Battles, M. B. et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat. Chem. Biol. 12, 87–93 (2016).
pubmed: 26641933
doi: 10.1038/nchembio.1982
Walters, M. S. et al. Generation of a human airway epithelium derived basal cell line with multipotent differentiation capacity. Respir. Res. 14, 135 (2013).
pubmed: 24298994
pmcid: 3907041
doi: 10.1186/1465-9921-14-135
Rameix-Welti, M. A. et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat. Commun. 5, 5104 (2014).
pubmed: 25277263
doi: 10.1038/ncomms6104
Hedstrom, L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem. Rev. 109, 2903–2928 (2009).
pubmed: 19480389
pmcid: 2737513
doi: 10.1021/cr900021w
Tong, X. et al. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antivir. Res. 149, 34–40 (2018).
pubmed: 29126899
doi: 10.1016/j.antiviral.2017.11.004
Mei-Jiao, G. et al. Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. Biomed. Pharmacother. 118, 109305 (2019).
pubmed: 31545264
doi: 10.1016/j.biopha.2019.109305
Markland, W., McQuaid, T. J., Jain, J. & Kwong, A. D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44, 859–866 (2000).
pubmed: 10722482
pmcid: 89783
doi: 10.1128/AAC.44.4.859-866.2000
Schopf, F. H., Biebl, M. M. & Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 18, 345–360 (2017).
pubmed: 28429788
doi: 10.1038/nrm.2017.20
Geller, R., Taguwa, S. & Frydman, J. Broad action of Hsp90 as a host chaperone required for viral replication. Biochim Biophys. Acta 1823, 698–706 (2012).
pubmed: 22154817
doi: 10.1016/j.bbamcr.2011.11.007
Wang, Y. et al. HSP90: a promising broad-spectrum antiviral drug target. Arch. Virol. 162, 3269–3282 (2017).
pubmed: 28780632
doi: 10.1007/s00705-017-3511-1
Lubkowska, A., Pluta, W., Stronska, A. & Lalko, A. Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection. Int J. Mol. Sci. 22, 9366 (2021).
pubmed: 34502274
pmcid: 8430838
doi: 10.3390/ijms22179366
Radhakrishnan, A. et al. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol. Cell Proteom. 9, 1829–1848 (2010).
doi: 10.1074/mcp.M110.001651
Geller, R., Andino, R. & Frydman, J. Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus. PLoS One 8, e56762 (2013).
pubmed: 23460813
pmcid: 3584091
doi: 10.1371/journal.pone.0056762
Porter, J. R., Fritz, C. C. & Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 14, 412–420 (2010).
pubmed: 20409745
doi: 10.1016/j.cbpa.2010.03.019
Li, Z. N. & Luo, Y. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncol. Rep. 49, 6 (2023).
pubmed: 36367182
doi: 10.3892/or.2022.8443
Pastey, M. K., Crowe, J. E. Jr. & Graham, B. S. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J. Virol. 73, 7262–7270 (1999).
pubmed: 10438814
pmcid: 104251
doi: 10.1128/JVI.73.9.7262-7270.1999
Gower, T. L. et al. RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology. J. Virol. 79, 5326–5336 (2005).
pubmed: 15827147
pmcid: 1082718
doi: 10.1128/JVI.79.9.5326-5336.2005
Gower, T. L., Peeples, M. E., Collins, P. L. & Graham, B. S. RhoA is activated during respiratory syncytial virus infection. Virology 283, 188–196 (2001).
pubmed: 11336544
doi: 10.1006/viro.2001.0891
Pastey, M. K., Gower, T. L., Spearman, P. W., Crowe, J. E. Jr. & Graham, B. S. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat. Med 6, 35–40 (2000).
pubmed: 10613821
pmcid: 7095870
doi: 10.1038/71503
Solski, P. A., Helms, W., Keely, P. J., Su, L. & Der, C. J. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ. 13, 363–373 (2002).
pubmed: 12193475
pmcid: 4415366
Johnson, S. M. et al. Respiratory Syncytial Virus Uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 11, e1005318 (2015).
pubmed: 26658574
pmcid: 4676609
doi: 10.1371/journal.ppat.1005318
Green, G. et al. CX3CR1 is a receptor for human respiratory syncytial virus in cotton rats. J. Virol. 95, e0001021 (2021).
pubmed: 34037420
doi: 10.1128/JVI.00010-21
Chemaly, R. F. et al. A Phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. Clin. Infect. Dis. 71, 2777–2786 (2020).
pubmed: 31793991
doi: 10.1093/cid/ciz1166
Marty, F. M. et al. A Phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract. Clin. Infect. Dis. 71, 2787–2795 (2020).
pubmed: 31915807
doi: 10.1093/cid/ciz1167
Porter, D. P. et al. Assessment of Drug Resistance during Phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus. Antimicrob. Agents Chemother. 64, e02312–e02319 (2020).
pubmed: 32071058
pmcid: 7449164
doi: 10.1128/AAC.02312-19
Groaz, E., De Clercq, E. & Herdewijn, P. Anno 2021: Which antivirals for the coming decade? Annu Rep. Med Chem. 57, 49–107 (2021).
pubmed: 34744210
pmcid: 8563371
Canini, L. et al. Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatol. Commun. 1, 288–292 (2017).
pubmed: 29404459
pmcid: 5721397
doi: 10.1002/hep4.1043
Blight, K. J., McKeating, J. A. & Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001–13014 (2002).
pubmed: 12438626
pmcid: 136668
doi: 10.1128/JVI.76.24.13001-13014.2002
Behrendt, P. et al. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antivir. Res. 147, 19–28 (2017).
pubmed: 28923507
doi: 10.1016/j.antiviral.2017.09.006
Jonsdottir, H. R. & Dijkman, R. Characterization of human coronaviruses on well-differentiated human airway epithelial cell cultures. Methods Mol. Biol. 1282, 73–87 (2015).
pubmed: 25720473
doi: 10.1007/978-1-4939-2438-7_8
McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).
pubmed: 24179220
pmcid: 4461862
doi: 10.1126/science.1243283
Krey, T. et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 6, e1000762 (2010).
pubmed: 20174556
pmcid: 2824758
doi: 10.1371/journal.ppat.1000762
Kabsch, W. Xds. Acta Crystallogr D. Biol. Crystallogr 66, 125–132 (2010).
pubmed: 20124692
pmcid: 2815665
doi: 10.1107/S0907444909047337
Evans, P. Scaling and assessment of data quality. Acta Crystallogr D. Biol. Crystallogr 62, 72–82 (2006).
pubmed: 16369096
doi: 10.1107/S0907444905036693
Agirre, J. et al. The CCP4 suite: integrative software for macromolecular crystallography. Acta Crystallogr D. Struct. Biol. 79, 449–461 (2023).
pubmed: 37259835
pmcid: 10233625
doi: 10.1107/S2059798323003595
Weinert, T. et al. Fast native-SAD phasing for routine macromolecular structure determination. Nat. Methods 12, 131–133 (2015).
pubmed: 25506719
doi: 10.1038/nmeth.3211
McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr 40, 658–674 (2007).
pubmed: 19461840
pmcid: 2483472
doi: 10.1107/S0021889807021206
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486–501 (2010).
pubmed: 20383002
pmcid: 2852313
doi: 10.1107/S0907444910007493
Bricogne, G. BE. et al. Womack T.O. BUSTER.) (2017).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D. Biol. Crystallogr 66, 12–21 (2010).
pubmed: 20057044
doi: 10.1107/S0907444909042073
Liebschner, D. et al. Polder maps: improving OMIT maps by excluding bulk solvent. Acta Crystallogr D. Struct. Biol. 73, 148–157 (2017).
pubmed: 28177311
pmcid: 5297918
doi: 10.1107/S2059798316018210